Phio Pharmaceuticals Corp. — Form 8-K Summary
Reporting date: October 13, 2026. The filing reports an operational milestone for the company’s PH-762 drug candidate.
Business context and milestone
Phio announced completion of its first commercial-scale cGMP batch of PH-762 drug substance. The company says this supports its plan to initiate a Phase 2b clinical trial in the first quarter of 2027.
Financial information
This 8-K does not report revenue, profit, cash flow, margins, debt, liquidity, or other financial results.
Outlook, risks, and contingencies
The stated trial timing is a plan, not a reported completed event. The filing text does not provide further guidance, risks, contingencies, or details about the batch beyond its successful completion.
Investor verification points
- Review Exhibit 99.1, the referenced press release, for additional information; its text is not included in the supplied filing content.
- Verify subsequent updates on the planned Phase 2b trial initiation and any related clinical or manufacturing developments.